Trump Announces Regeneron Deal To Cut Medicaid And TrumpRx Drug Prices
Former President Donald Trump announced in a video released Wednesday that he had struck a deal with drugmaker Regeneron to lower Regeneron drug prices for Medicaid beneficiaries and for sales through his "TrumpRx" program.
He said the arrangement would reduce costs for patients and for government payers and that discounted medicines would be available via TrumpRx. Regeneron did not immediately respond to requests for comment.
The announcement comes as drug pricing remains a persistent political issue and as Trump's campaign has prioritized prescription cost cuts. Regeneron became widely known for its monoclonal antibody COVID treatment, and drugmakers' prices have been a flashpoint in debates over Medicaid spending.
It was not clear how the deal would operate under federal Medicaid rules or whether claimed savings would require new legislation. Questions remain about which drugs are included, the size of any discounts, and how the agreement would be enforced.
đ Key Facts
- Trump announced the Regeneron deal at the White House on April 23, 2026.
- Regeneron agreed to lower prices for all its current and future drugs on Medicaid and sell Praluent for $225 on TrumpRx.
- Regeneron pledged $27 billion in U.S. research, development, and manufacturing investment as part of the agreement.
- Regeneron's gene therapy Otarmeni for rare congenital hearing loss received expedited FDA approval and will be provided free to eligible U.S. patients.
- The FDA used its Commissioner's National Priority Voucher program, which lacks explicit congressional authorization and is under Democratic scrutiny for ties to White House pricing deals.
đ° Source Timeline (1)
Follow how coverage of this story developed over time